Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ERGIC3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The ERGIC3 protein also known as ERGIC-53 plays a critical role in the early secretory pathway. It is involved in vesicular trafficking between the endoplasmic reticulum and the Golgi apparatus. Weighing around 38 kDa ERGIC3 is an important contributor to cargo transport processes. The protein finds expression in various tissues predominantly within cells that have high secretory demands.
Biological function summary
The ERGIC3 protein functions as part of the larger ER-Golgi intermediate compartment (ERGIC) complex helping in the sorting and transport of proteins. The ERGIC serves as an essential hub in the secretory pathway modulating cargo movement to the Golgi for further processing. Some studies have implicated ERGIC3 in maintaining Golgi integrity and optimal function affecting overall cellular health.
Pathways
ERGIC3 plays a significant role in the secretory pathway assisting in the transit of proteins and the correct folding of polypeptides. It links functionally to other key proteins such as KI67 which associates with cell proliferation regions and relies heavily on efficient protein processing for cellular division. The association suggests ERGIC3's involvement in maintaining cellular growth and regeneration.
Researchers have connected ERGIC3 with diseases like congenital disorders of glycosylation due to its role in protein folding and trafficking. Furthermore disruptions in ERGIC3 function have correlations with cancer progression particularly in overactive secretion conditions. These disorders often coincide with aberrant expression or mutations in folding-related proteins signifying potential ERGIC3 involvement in pathological manifestations when its function is compromised.
